Overview Dividends

(PCRX) Pacira BioSciences - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6951271005

Bupivacaine,Anesthetic,Injectable

PCRX EPS (Earnings per Share)

EPS Growth (3Y CAGR): 5.42%
EPS Trend (3Y Correlation): 25.3%

PCRX Revenue

Revenue Growth (3Y CAGR): 2.89%
Revenue Trend (3Y Correlation): 52.5%

Description: PCRX Pacira BioSciences

Pacira BioSciences, Inc. (NASDAQ:PCRX) is a US-based pharmaceutical company. To evaluate its stock, we need to focus on key drivers and KPIs that influence its market performance.

The companys market capitalization stands at $1.113 billion, indicating a moderate size in the pharmaceutical industry. The forward Price-to-Earnings ratio is 8.76, suggesting that investors have certain expectations for future earnings growth. However, the current Return on Equity (RoE) is negative at -16.53%, indicating that the company is currently unprofitable.

To understand the potential for future profitability, we need to examine the companys product pipeline, revenue growth, and operating expenses. Key economic drivers for PCRX include the demand for its pharmaceutical products, competition in the market, and the overall regulatory environment. The companys ability to manage its tax provision effectively, as reflected in its quarterly reports, is also crucial.

From a trading perspective, PCRX has shown volatility, with an Average True Range (ATR) of 0.97, representing a 3.84% daily price movement. The stocks beta is 0.481, indicating relatively lower volatility compared to the overall market. To make informed trading decisions, its essential to monitor the stocks moving averages, such as SMA20, SMA50, and SMA200, which currently indicate a positive trend.

To further assess the stocks potential, we should analyze the companys revenue growth rate, gross margin, and operating cash flow. These metrics will provide insights into PCRXs financial health and its ability to generate cash to invest in its business or return value to shareholders.

PCRX Stock Overview

Market Cap in USD	1,223m
Sub-Industry	Pharmaceuticals
IPO / Inception	2011-02-03

PCRX Stock Ratings

Growth Rating	-16.0%
Fundamental	49.3%
Dividend Rating	-
Return 12m vs S&P 500	67.5%
Analyst Rating	3.33 of 5

PCRX Dividends

Currently no dividends paid

PCRX Growth Ratios

Growth Correlation 3m	62.7%
Growth Correlation 12m	70.4%
Growth Correlation 5y	-91.3%
CAGR 5y	-21.30%
CAGR/Max DD 3y	-0.27
CAGR/Mean DD 3y	-0.43
Sharpe Ratio 12m	0.13
Alpha	93.16
Beta	0.561
Volatility	39.88%
Current Volume	1010.8k
Average Volume 20d	606.8k
Stop Loss	25.7 (-4.3%)
Signal	-0.38

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (-127.5m TTM) > 0 and > 6% of Revenue (6% = 42.4m TTM)

FCFTA 0.08 (>2.0%) and ΔFCFTA -3.60pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 61.27% (prev 78.16%; Δ -16.89pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.09 (>3.0%) and CFO 134.5m > Net Income -127.5m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 2.38 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (45.5m) change vs 12m ago -10.05% (target <= -2.0% for YES)

Gross Margin 78.19% (prev 67.83%; Δ 10.37pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 44.34% (prev 41.92%; Δ 2.42pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -5.08 (EBITDA TTM -455.0k / Interest Expense TTM 17.8m) >= 6 (WARN >= 3)

Altman Z'' 0.75

(A) 0.28 = (Total Current Assets 745.6m - Total Current Liabilities 313.2m) / Total Assets 1.54b

(B) -0.13 = Retained Earnings (Balance) -206.4m / Total Assets 1.54b

(D) -0.26 = Book Value of Equity -202.3m / Total Liabilities 779.5m

Total Rating: 0.75 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 49.30

1. Piotroski 4.50pt = -0.50

2. FCF Yield 8.56% = 4.28

3. FCF Margin 16.59% = 4.15

4. Debt/Equity 0.78 = 2.21

5. Debt/Ebitda data missing

6. ROIC - WACC -12.29% = -12.50

7. RoE -16.53% = -2.50

8. Rev. Trend 52.52% = 2.63

9. Rev. CAGR 2.89% = 0.36

10. EPS Trend 25.35% = 0.63

11. EPS CAGR 5.42% = 0.54

What is the price of PCRX shares?

As of September 16, 2025, the stock is trading at USD 26.86 with a total of 1,010,755 shares traded.
Over the past week, the price has changed by +0.45%, over one month by +8.39%, over three months by +10.35% and over the past year by +99.11%.

Is Pacira BioSciences a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Pacira BioSciences (NASDAQ:PCRX) is currently (September 2025) a stock to sell. It has a ValueRay Fundamental Rating of 49.30 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PCRX is around 26.02 USD . This means that PCRX is currently overvalued and has a potential downside of -3.13%.

Is PCRX a buy, sell or hold?

Pacira BioSciences has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold PCRX.

Strong Buy: 1
Buy: 1
Hold: 3
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the PCRX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	29	8%
Analysts Target Price	29	8%
ValueRay Target Price	28.3	5.2%

Last update: 2025-09-03 04:45

PCRX Fundamental Data Overview

Market Cap USD = 1.22b (1.22b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 445.9m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 9.4251
P/S = 1.7328
P/B = 1.5814
P/EG = -3.83
Beta = 0.481
Revenue TTM = 705.8m USD
EBIT TTM = -90.4m USD
EBITDA TTM = -455.0k USD
Long Term Debt = 378.1m USD (from longTermDebt, last quarter)
Short Term Debt = 212.0m USD (from shortTermDebt, last quarter)
Debt = 590.1m USD (Calculated: Short Term 212.0m + Long Term 378.1m)
Net Debt = 330.9m USD (from netDebt column, last quarter)
Enterprise Value = 1.37b USD (1.22b + Debt 590.1m - CCE 445.9m)
Interest Coverage Ratio = -5.08 (Ebit TTM -90.4m / Interest Expense TTM 17.8m)
FCF Yield = 8.56% (FCF TTM 117.1m / Enterprise Value 1.37b)
FCF Margin = 16.59% (FCF TTM 117.1m / Revenue TTM 705.8m)
Net Margin = -18.06% (Net Income TTM -127.5m / Revenue TTM 705.8m)
Gross Margin = 78.19% ((Revenue TTM 705.8m - Cost of Revenue TTM 153.9m) / Revenue TTM)
Tobins Q-Ratio = -6.76 (set to none) (Enterprise Value 1.37b / Book Value Of Equity -202.3m)
Interest Expense / Debt = 0.65% (Interest Expense 3.85m / Debt 590.1m)
Taxrate = 21.0% (US default)
NOPAT = -90.4m (EBIT -90.4m, no tax applied on loss)
Current Ratio = 2.38 (Total Current Assets 745.6m / Total Current Liabilities 313.2m)
Debt / Equity = 0.78 (Debt 590.1m / last Quarter total Stockholder Equity 757.8m)
Debt / EBITDA = -1297 (Net Debt 330.9m / EBITDA -455.0k)
Debt / EBITDA = -1297 --> set to None
Debt / FCF = 5.04 (Debt 590.1m / FCF TTM 117.1m)
Total Stockholder Equity = 771.1m (last 4 quarters mean)
RoA = -8.29% (Net Income -127.5m, Total Assets 1.54b )
RoE = -16.53% (Net Income TTM -127.5m / Total Stockholder Equity 771.1m)
RoCE = -7.87% (Ebit -90.4m / (Equity 771.1m + L.T.Debt 378.1m))
RoIC = -6.67% (NOPAT -90.4m / Invested Capital 1.36b)
WACC = 5.62% (E(1.22b)/V(1.81b) * Re(8.08%)) + (D(590.1m)/V(1.81b) * Rd(0.65%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 3.03 | Cagr: -0.07%
Discount Rate = 8.08% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 81.33% ; FCFE base≈144.1m ; Y1≈177.8m ; Y5≈303.4m
Fair Price DCF = 114.1 (DCF Value 5.13b / Shares Outstanding 44.9m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 25.35 | EPS CAGR: 5.42% | SUE: 0.27 | # QB: False
Revenue Correlation: 52.52 | Revenue CAGR: 2.89%

Additional Sources for PCRX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle